Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 4 2Phase 1 2Phase 2 1

Status

Unknown 3Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Papillomavirus Infections 6Condylomata Acuminata 3Uterine Cervical Neoplasms 2Herpes Zoster 2Anus Neoplasms 2Whooping Cough 1Vulvar Neoplasms 1Vaginal Neoplasms 1Tetanus 1Neoplasms, Glandular and Epithelial 1Meningitis 1Hematologic Neoplasms 1HIV Infections 1Diphtheria 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 22Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 15Papillomavirus Vaccines 9Vaccines 6Blood Specimen Collection 4Watchful Waiting 2Vaccines, Synthetic 2Light Coagulation 2Hepatitis A Vaccines 2Engerix-B 2lime 1halofantrine 1Sodium Chloride 1Radiotherapy, Intensity-Modulated 1Pentetic Acid 1Olive Oil 1Observation 1Measles-Mumps-Rubella Vaccine 1Laser Therapy 1Injections 1Imiquimod 1Human Papillomavirus DNA Tests 1Fluorouracil 1Diphtheria-Tetanus-acellular Pertussis Vaccines 1DTPa-HBV-IPV combined vaccine 1Colposcopy 1Clinical Protocols 1Cisplatin 1Circumcision, Male 1Chorionic Villi Sampling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Papillomavirus Infections × Vaccines × Clear all
NCT06207175 2024-01-23

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

Beijing Health Guard Biotechnology, Inc

Phase 3 Unknown
1,260 enrolled

Papillomavirus Infections

NCT04965350 2023-04-13

Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females

Shanghai Zerun Biotechnology Co.,Ltd

Phase 3 Completed
1,100 enrolled

Papillomavirus Infections

NCT05668572 2023-01-04

A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

Beijing Health Guard Biotechnology, Inc

Phase 3 Unknown
12,000 enrolled

Papillomavirus Infections

NCT05662020 2022-12-27

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Beijing Health Guard Biotechnology, Inc

Phase 3 Active not recruiting
2,750 enrolled
GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT01984697 2018-08-08

V503-010

Merck Sharp & Dohme LLC

Phase 3 Completed
1,518 enrolled 44 charts

Papillomavirus Infections

NCT01512784 2012-01-19

Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults

University of Milan

Phase 3 Unknown
100 enrolled

HIV Infections, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡